Extended Followup and Risk Factors for Disease Reclassification in a Large Active Surveillance Cohort for Localized Prostate Cancer-Reference-Cited by-同舟云学术

Extended Followup and Risk Factors for Disease Reclassification in a Large Active Surveillance Cohort for Localized Prostate Cancer

Published:2015-03 Issue:3 Volume:193 Page:807-811
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

Welty Christopher J.¹,Cowan Janet E.¹,Nguyen Hao¹,Shinohara Katsuto¹,Perez Nannette¹,Greene Kirsten L.¹,Chan June M.¹,Meng Maxwell V.¹,Simko Jeffry P.¹,Cooperberg Matthew R.¹,Carroll Peter R.¹

Affiliation:

1. Department of Urology, University of California-San Francisco Helen Diller Family Comprehensive Cancer Center, University of California-San Francisco, San Francisco, California

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Reference30 articles.

1. Cancer Facts & Figures 2014,2014

2. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management;Cooperberg;J Clin Oncol,2004

3. 20-year outcomes following conservative management of clinically localized prostate cancer;Albertsen;JAMA,2005

4. Active surveillance: oncologic outcome;Venderbos;Curr Opin Urol,2013

5. Active surveillance: the Canadian experience;Klotz,2012

Cited by 145 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Active surveillance selection and 3-year durability in intermediate-risk prostate cancer following genomic testing;Prostate Cancer and Prostatic Diseases;2024-09-05

2. Long-term outcomes of the first prospective study of active surveillance for prostate cancer in Japan;International Journal of Clinical Oncology;2024-08-01

3. Outcomes of active surveillance for Japanese patients with prostate cancer (PRIAS‐JAPAN);BJU International;2024-06-17

4. The evolving landscape: magnetic resonance imaging in active surveillance for prostate cancer management;Frontiers in Urology;2024-04-12

5. What is cancer? A focus on Grade Group 1 prostate cancer;BJU International;2024-01-16